Episode summary
Novo Nordisk Gets US Approval for Wegovy Obesity Pill | Bloomberg Intelligence
Bloomberg Intelligence
· · Hosts: Paul Sweeney, Scarlet Fu · Guests: John Tozzi, Reshmi Basu, George Ferguson, Nathan Dean
Summary
Novo Nordisk’s U.S. approval for a Wegovy pill was framed as a major milestone for the obesity-drug market, but not a permanent lead. The host said the company is “going all in” on weight loss drugs, and a guest argued the pill’s key advantage is that it offers the same efficacy as the injection with more convenience. John Tozzi said Eli Lilly is close behind and could win approval for its own oral obesity treatment as soon as March, so the competitive picture is still fluid even after Novo’s first-mover win.
The discussion then turned to Saks Global Enterprises, where a guest said the company is running out of cash and Chapter 11 is a real possibility. The report emphasized more than $100 million of debt coming due at the end of the month, weak vendor relations, and distressed trading in the capital structure, including debt pricing in the single digits.
The episode also covered airline profitability and 2026 policy risks. George Ferguson said full-service carriers are adding capacity and premium seats, while weak pricing could pressure fares. Nathan Dean argued 2026 will be dominated by deregulation, tariffs, and election-year gridlock, with crypto, financials, clean energy, and AI among the sectors most exposed to policy shifts.
Key takeaways
- John Tozzi said Novo Nordisk’s pill approval is a milestone, but Eli Lilly could still get its own oral obesity drug approved as soon as March.
- The host said Novo’s main selling point is convenience plus efficacy, since the pill is marketed with 17% weight-loss efficacy in the company’s claims.
- A guest said Saks Global is running out of cash and Chapter 11 is a possibility, with more than $100 million due at month-end.
- Rashmi Basu said Saks’ debt is already trading at distress levels, including junior notes around 7.5 cents on the dollar.
- George Ferguson said 2026 airline capacity growth from the big carriers could pressure premium-seat pricing and margins.
- Nathan Dean said 2026 should favor crypto and financials through deregulation, while election-year politics and tariffs make legislation harder to pass.
Notable quotes
“This is really going to be super exciting for the millions of patients that have been waiting to get their hands on a GLP-1 pill”
“for the first time we are having a pill that has an efficacy of some 17% if you take the pill regularly”
“The quick answer is yes. We're going all in”
“A chapter 11 is a possibility given that the company is running out of cash”
“I think this will just be big for a lot of folks and hopefully the cost will continue to come down”
How the episode opens
Bloomberg Audio Studios podcasts radio news. You're listening to the Bloomberg Intelligence Podcast. Catch us live weekdays at 10 a.m. Eastern — On Apple CarPlay and Android Auto with the Bloomberg Business App. — Listen on demand wherever you get your podcasts or watch us live on YouTube. Well, we talked about how Nova Nordisk is one of the big movers today in early trading. The president and CEO of the drug maker says the company is going allin on weight loss drugs as his company is the first uh to come out with a pill to be sold in the US market. He spoke with our Katie Griffeld earlier today.
This is really going to be super exciting for the millions of patients that have been waiting to get their hands on a GLP-1 pill. Um and for the first time we are having a pill that has an efficacy of some 17% if you take the pill regularly and one in three people are going to actually reduce up to 20% weight loss. I think that data speaks for itself and we are super excited of course to be the first to the market and um and we're going to give go all in trying to make this a huge success.
Well, moving forward, I mean, beyond just these uh first few months after Eli Liy does have their pill on the market, how do you plan to compete? What is your strategy there given my understanding is that there's likely going to be no restrictions when it comes to food, when it comes to drinks around Lily's version.
Yeah. So, as I mentioned, there are no other phase three trials of oral GOP 1 that has shown this level efficacy. This means that for the first time ever people do not to have compromise between either taking a efficacious injection or a convenient pill.
From the episode’s captions: roughly the first two minutes, lightly cleaned. Keep watching on YouTube →
Topics
- wegovy approval
- obesity drug market
- us airline outlook 2026
- chapter 11 bankruptcy
- 2025 winners losers
Companies and tickers mentioned
- NVO
- Novo Nordisk
- Saks Global Enterprises
Watch the episode
Watch “Novo Nordisk Gets US Approval for Wegovy Obesity Pill | Bloomberg Intelligence” on YouTube
Summary, takeaways and quote selection by Octagon. Quotes are short excerpts; the full conversation is in the episode.
More from Bloomberg Intelligence
-
Anthropic’s IPO Is Said to Be About Six Times Oversubscribed | Bloomberg Intelligence -
Instant Reaction: Nvidia CEO Jensen Huang Ousted by Nvidia Board | Bloomberg Intelligence -
Nvidia’s Huang Ousted by Board in Move That Roils AI Economy | Bloomberg Intelligence -
CoreWeave Shares Soar After AI Computing Firm Eases Debt Fears | Bloomberg Intelligence -
Anthropic Targets $1.4 Trillion Valuation in Blockbuster IPO | Bloomberg Intelligence -
Nvidia Probe Into CEO Affair Raises Thorny Questions for AI | Bloomberg Intelligence
Bloomberg Intelligence, this episode and its artwork belong to Bloomberg. Octagon is not affiliated with the show; this page is an independent summary.
